^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Squamous Cell Skin Cancer
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    07/01/2021
    Excerpt:
    KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated...for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation.
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    07/14/2020
    Excerpt:
    Squamous Cell Skin Cancer: Preferred regimens…Regional Recurrence or Distant Metastatic Disease...Pembrolizumab